{
  "guideline": {
    "id": "PA166192301",
    "name": "Annotation of CPIC Guideline for meloxicam and CYP2C9",
    "source": "CPIC",
    "version": 8,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166192301",
    "relatedChemicals": [
      {
        "id": "PA450353",
        "name": "meloxicam",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166298197",
      "name": "Recommendation PA166298197",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450353",
          "name": "meloxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060799,
        "html": "<p>Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).</p>\n"
      },
      "implications": [
        "CYP2C9: Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
      ],
      "lookupKey": {
        "CYP2C9": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298193",
      "name": "Recommendation PA166298193",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450353",
          "name": "meloxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060795,
        "html": "<p>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298198",
      "name": "Recommendation PA166298198",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450353",
          "name": "meloxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060800,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C9: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298194",
      "name": "Recommendation PA166298194",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450353",
          "name": "meloxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060796,
        "html": "<p>Initiate therapy with recommended starting dose. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.</p>\n"
      },
      "implications": [
        "CYP2C9: Mildly reduced metabolism"
      ],
      "lookupKey": {
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298195",
      "name": "Recommendation PA166298195",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450353",
          "name": "meloxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060797,
        "html": "<p>Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.</p>\n"
      },
      "implications": [
        "CYP2C9: Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities"
      ],
      "lookupKey": {
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298196",
      "name": "Recommendation PA166298196",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450353",
          "name": "meloxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060798,
        "html": "<p>Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).</p>\n"
      },
      "implications": [
        "CYP2C9: Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
      ],
      "lookupKey": {
        "CYP2C9": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "32189324",
      "title": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.",
      "authors": [
        "Theken Katherine N",
        "Lee Craig R",
        "Gong Li",
        "Caudle Kelly E",
        "Formea Christine M",
        "Gaedigk Andrea",
        "Klein Teri E",
        "Agúndez José A G",
        "Grosser Tilo"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2020
    }
  ],
  "version": "2023-12-19-10-38"
}